PARTNER: Psoriatic Arthritis and other Comorbidities in Patients with Psoriasis
This course is currently closed
2 CPD points with the RACGP
1 Educational activity hour with the ACRRM
All participants will be awarded a certificate of completion for self-reporting to other colleges
In collaboration with GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) and the Australasian College of Dermatologists Proudly supported by Psoriasis Australia
This interactive e-module will take about 60 minutes to complete and includes:
Recorded audio from 2 patients with psoriasis and psoriatic arthritis
Tips and tools for screening and diagnosing psoriatic arthritis
Real patient stories (not just cases), from symptoms to treatment
Common comorbidities in psoriasis – do you know the leading cause of death?
How to monitor patients who are on biologics
Learning objectives: Upon completing this course, you will be able to:
Differentiate the outcomes for psoriatic arthritis patients who are diagnosed, referred and treated as early as symptoms are recognised
Be aware of the associated cardiovascular, metabolic and psychosocial comorbidities
Identify process changes needed in practice to recognise psoriatic arthritis symptoms early
Independent Medical Education This programme was supported by an independent educational grant from Pfizer IGLC. Pfizer had no influence on the content or involvement in the development of the programme or the selection of faculty.
A/Prof Peter Nash Department of Medicine, University of Queensland; Director, Rheumatology Research Unit, Sunshine Coast; member of the International Steering Committee for Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
Dr Nash has received grants for research and clinical trials and honoraria for advice and lectures from AbbVie, Amgen, Bristol–Myers Squibb, Eli Lilly, Janssen, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and UCB.